Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management

The Lancet Neurology

Volumn 9, Issue 1, 2010, Pages 77-93

  Bushby, Katharine ^a   Finkel, Richard ^b   Birnkrant, David J ^c   Case, Laura E ^d   Clemens, Paula R ^e   Cripe, Linda ^f   Kaul, Ajay ^f   Kinnett, Kathi ^f   McDonald, Craig ^g   Pandya, Shree ^h   Poysky, James ⁱ   Shapiro, Frederic ^j   Tomezsko, Jean ^b   Constantin, Carolyn ^k  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c METROHEALTH MEDICAL CENTER   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

ⁱ BAYLOR COLLEGE OF MEDICINE   (United States)

^j BOSTON CHILDREN S HOSPITAL   (United States)

^k NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTIOXIDANT; CARNITINE; DEFLAZACORT; GLUCOCORTICOID; OXANDROLONE; PREDNISOLONE; PREDNISONE; UBIDECARENONE;

CLINICAL ASSESSMENT; CLINICAL TRIAL; COGNITION; DIAGNOSTIC ACCURACY; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DUCHENNE MUSCULAR DYSTROPHY; HEALTH CARE DELIVERY; HEALTH CARE MANAGEMENT; HEALTH CARE QUALITY; HEALTH SERVICE; HUMAN; LOW DRUG DOSE; MUSCLE BIOPSY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RECOMMENDED DRUG DOSE; REVIEW; SCOLIOSIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

DIAGNOSIS, DIFFERENTIAL; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MUSCULAR DYSTROPHY, DUCHENNE;

EID: 72149108443     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(09)70271-6     Document Type: Review

References (96)

1. Drousiotou A., Ioannou P., Georgiou T., et al. Neonatal screening for Duchenne muscular dystrophy: a novel semiquantitative application of the bioluminescence test for creatine kinase in a pilot national program in Cyprus. Genet Test 2 (1998) 55-60
2. Bradley D., and Parsons E. Newborn screening for Duchenne muscular dystrophy. Semin Neonatol 3 (1998) 27-34
3. Emery A.E. Population frequencies of inherited neuromuscular diseases-a world survey. Neuromuscul Disord 1 (1991) 19-29
4. Bushby K.M., Hill A., and Steele J.G. Failure of early diagnosis in symptomatic Duchenne muscular dystrophy. Lancet 353 (1999) 55-78
5. Poysky J., and Behavior in DMD Study Group. Behavior patterns in Duchenne muscular dystrophy: report on the Parent Project Muscular Dystrophy behavior workshop 8-9 of December 2006, Philadelphia, USA. Neuromuscul Disord 17 (2007) 986-994
6. Hoffman E.P., Brown Jr. R.H., and Kunkel L.M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51 (1987) 919-928
7. Nicholson L.V., Johnson M.A., Bushby K.M., Gardner-Medwin D., Curtis A., and Ginjaar I.B. Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 1. Trends across the clinical groups. J Med Genet 30 (1993) 728-736
8. Nicholson L.V., Johnson M.A., Bushby K.M., Gardner-Medwin D., Curtis A., and Ginjaar I.B. Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 2. Correlations within individual patients. J Med Genet 30 (1993) 737-744
9. Nicholson L.V., Johnson M.A., Bushby K.M., Gardner-Medwin D., Curtis A., and Ginjaar I.B. Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 3. Differential diagnosis and prognosis. J Med Genet 30 (1993) 745-751
10. Towbin J.A. The role of cytoskeletal proteins in cardiomyopathies. Curr Opin Cell Biol 10 (1998) 131-139
11. Towbin J., and Bowles N.E. Molecular genetics of left ventricular dysfunction. Curr Mol Med 1 (2001) 81-90
12. Muntoni F., Torelli S., and Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol 2 (2003) 731-740
13. Bushby K.M., Goodship J.A., Nicholson L.V., et al. Variability in clinical, genetic and protein abnormalities in manifesting carriers of Duchenne and Becker muscular dystrophy. Neuromuscul Disord 3 (1993) 57-64
14. Richards C.S., Watkins S.C., Hoffman E.P., et al. Skewed X inactivation in a female MZ twin results in Duchenne muscular dystrophy. Am J Hum Genet 46 (1990) 672-681
15. Hoffman E.P., Arahata K., Minetti C., Bonilla E., and Rowland L.P. Dystrophinopathy in isolated cases of myopathy in females. Neurology 42 (1992) 967-975
16. Koenig M., Hoffman E.P., Bertelson C.J., Monaco A.P., Feener C., and Kunkel L.M. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50 (1987) 509-517
17. Kunkel L.M., Monaco A.P., Hoffman E., Koenig M., Feener C., and Bertelson C. Molecular studies of progressive muscular dystrophy (Duchenne). Enzyme 38 (1987) 72-75
18. Muntoni F., and Wells D. Genetic treatments in muscular dystrophies. Curr Opin Neurol 20 (2007) 590-594
19. Manzur A.Y., Kuntzer T., Pike M., and Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 1 (2008) CD003725.
20. Moxley III R.T., Ashwal S., Pandya S., et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 64 (2005) 13-20
21. Jeppesen J., Green A., Steffensen B.F., and Rahbek J. The Duchenne muscular dystrophy population in Denmark, 1977-2001: prevalence, incidence and survival in relation to the introduction of ventilator use. Neuromuscul Disord 13 (2003) 804-812
22. Yasuma F., Konagaya M., Sakai M., Kuru S., and Kawamura T. A new lease on life for patients with Duchenne muscular dystrophy in Japan. Am J Med 117 (2004) 363
23. Eagle M., Bourke J., Bullock R., et al. Managing Duchenne muscular dystrophy-the additive effect of spinal surgery and home nocturnal ventilation in improving survival. Neuromuscul Disord 17 (2007) 470-475
24. Eagle M. Report on the muscular dystrophy campaign workshop: exercise in neuromuscular diseases Newcastle, January 2002. Neuromuscul Disord 12 (2002) 975-983
25. Markham L.W., Kinnett K., Wong B.L., Benson D.W., and Cripe L.H. Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. Neuromuscul Disord 18 (2008) 365-370
26. American Academy of Pediatrics Section on Cardiology and Cardiac Surgery. Cardiovascular health supervision for individuals affected by Duchenne or Becker muscular dystrophy. Pediatrics 116 (2005) 1569-1573
27. Bushby K., Muntoni F., and Bourke J.P. 107th ENMC International Workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th-9th June 2002, Naarden, the Netherlands. Neuromuscul Disord 13 (2003) 166-172
28. Duboc D., Meune C., Lerebours G., Devaux J.Y., Vaksmann G., and Bécane H.M. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol 45 (2005) 855-857
29. Brooke M.H., Fenichel G.M., Griggs R.C., Mendell J.R., Moxley R.T., and CIDD Group. Duchenne muscular dystrophy: patterns of clinical progression and effects of supportive therapy. Neurology 39 (1989) 475-481
30. Vignos P.J., Wagner M.B., Karlinchak B., and Katirji B. Evaluation of a program for long-term treatment of Duchenne muscular dystrophy. Experience at the University Hospitals of Cleveland. J Bone Joint Surg Am 78 (1996) 1844-1852
31. Rahbek J., Werge B., Madsen A., Marquardt J., Steffensen B.F., and Jeppesen J. Adult life with Duchenne muscular dystrophy: observations among an emerging and unforeseen patient population. Pediatr Rehabil 8 (2005) 17-28
32. Tatara K., and Shinno S. Management of mechanical ventilation and prognosis in duchenne muscular dystrophy. IRYO Jap J Natl Med Serv 62 (2008) 566-571
33. Parent Project Muscular Dystrophy. MD-CARE Act. http://www.parentprojectmd.org/site/PageServer?pagename=ending_speakup_m dcareact (accessed Oct 7, 2009).
34. Bushby K., Finkel R., Birnkrant D.J., et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implemenetation of multidisciplinary care. Lancet Neurol (2009) 10.1016/S1474-4422(09)70272-8 published online Nov 30.
35. Fitch K., Bernstein S.J., Aguilar M.S., et al. The RAND/UCLA appropriateness method user's manual (2001), RAND Corporation, Santa Monica, CA
36. Parsons E.P., Clark A.J., and Bradley D.M. Developmental progress in Duchenne muscular dystrophy: lessons for earlier detection. Eur J Paediatr Neurol 8 (2004) 145-153
37. Prior T.W., and Bridgeman S.J. Experience and strategy for the molecular testing of Duchenne muscular dystrophy. J Mol Diagn 7 (2005) 317-326
38. Lalic T., Vossen R.H., Coffa J., et al. Deletion and duplication screening in the DMD gene using MLPA. Eur J Hum Genet 13 (2005) 1231-1234
39. Flanigan K.M., von Niederhausern A., Dunn D.M., Alder J., Mendell J.R., and Weiss R.B. Rapid direct sequence analysis of the dystrophin gene. Am J Hum Genet 72 (2003) 931-939
40. Dent K.M., Dunn D.M., von Niederhausern A.C., et al. Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort. Am J Med Genet A 134 (2005) 295-298
41. Lim L.E., and Rando T.A. Technology insight: therapy for Duchenne muscular dystrophy-an opportunity for personalized medicine?. Nat Clin Pract Neurol 4 (2008) 149-158
42. van Ommen G.J., van Deutekom J., and Aartsma-Rus A. The therapeutic potential of antisense-mediated exon skipping. Curr Opin Mol Ther 10 (2008) 140-149
43. van Deutekom J.C., Janson A.A., Ginjaar I.B., et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 357 (2007) 2677-2686
44. Muntoni F. Is a muscle biopsy in Duchenne dystrophy really necessary?. Neurology 57 (2001) 574-575
45. Lacomis D. The use of percutaneous needle muscle biopsy in the diagnosis of myopathy. Curr Rheumatol Rep 2 (2000) 225-229
46. Lacomis D. The utility of muscle biopsy. Curr Neurol Neurosci Rep 4 (2004) 81-86
47. Henriksson K.G. Semi-open muscle biopsy technique. A simple outpatient procedure. Acta Neurol Scand 59 (1979) 317-323
48. Dorph C., Nennesmo I., and Lundberg I.E. Percutaneous conchotome muscle biopsy. A useful diagnostic and assessment tool. J Rheumatol 28 (2001) 1591-1599
49. Beenakker E.A., Maurits N.M., Fock J.M., Brouwer O.F., and van der Hoeven J.H. Functional ability and muscle force in healthy children and ambulant Duchenne muscular dystrophy patients. Eur J Paediatr Neurol 9 (2005) 387-393
50. Florence J.M., Pandya S., King W.M., et al. Clinical trials in Duchenne dystrophy. Standardization and reliability of evaluation procedures. Phys Ther 64 (1984) 41-45
51. Pandya S., Florence J.M., King W.M., Robinson J., Signore L.C., and CIDD Group. Reliability of goniometric measurements in patients with Duchenne muscular dystrophy. Phys Ther 65 (1985) 1339-1342
52. Brooke M.H., Griggs R.C., Mendell J.R., Fenichel G.M., Shumate J.B., and Pellegrino R.J. Clinical trial in Duchenne dystrophy. 1. The design of the protocol. Muscle Nerve 4 (1981) 186-197
53. Gorospe J.R., and Hoffman E.P. Duchenne muscular dystrophy. Curr Opin Rheumatol 4 (1992) 794-800
54. Matsumura K., Ohlendieck K., Ionasescu V.V., et al. The role of the dystrophin-glycoprotein complex in the molecular pathogenesis of muscular dystrophies. Neuromuscul Disord 3 (1993) 533-535
55. Johnson E.W., and Walter J. Zeiter Lecture: pathokinesiology of Duchenne muscular dystrophy: implications for management. Arch Phys Med Rehabil 58 (1977) 4-7
56. McDonald C.M., Abresch R.T., Carter G.T., et al. Profiles of neuromuscular diseases. Duchenne muscular dystrophy. Am J Phys Med Rehabil 74 suppl (1995) S70-S92
57. Siegel I.M. Pathomechanics of stance in Duchenne muscular dystrophy. Arch Phys Med Rehabil 53 (1972) 403-406
58. Sutherland D.H., Olshen R., Cooper L., et al. The pathomechanics of gait in Duchenne muscular dystrophy. Dev Med Child Neurol 23 (1981) 3-22
59. Angelini C. The role of corticosteroids in muscular dystrophy: a critical appraisal. Muscle Nerve 36 (2007) 424-435
60. Bushby K., Muntoni F., Urtizberea A., Hughes R., and Griggs R. Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids. 2-4 April 2004, Naarden, The Netherlands. Neuromuscul Disord 14 (2004) 526-534
61. King W.M., Ruttencutter R., Nagaraja H.N., et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology 68 (2007) 1607-1613
62. Biggar W.D., Harris V.A., Eliasoph L., and Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 16 (2006) 249-255
63. Houde S., Filiatrault M., Fournier A., et al. Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up. Pediatr Neurol 38 (2008) 200-206
64. Griggs R.C., Moxley III R.T., Mendell J.R., et al. Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Arch Neurol 48 (1991) 383-388
65. Mendell J.R., Moxley R.T., Griggs R.C., et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med 320 (1989) 1592-1597
66. Fenichel G.M., Mendell J.R., Moxley R.T., et al. A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy. Arch Neurol 48 (1991) 575-579
67. Mesa L.E., Dubrovsky A.L., Corderi J., Marco P., and Flores D. Steroids in Duchenne muscular dystrophy-deflazacort trial. Neuromuscul Disord 1 (1991) 261-266
68. Biggar W.D., Politano L., Harris V.A., et al. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. Neuromuscul Disord 14 (2004) 476-482
69. Fenichel G.M., Florence J.M., Pestronk A., et al. Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology 41 (1991) 1874-1877
70. Bonifati M.D., Ruzza G., Bonometto P., et al. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve 23 (2000) 1344-1347
71. American Academy of Pediatrics Committee, and Kleinman R.E. Pediatric nutrition handbook. 6th edn. (2009), American Academy of Pediatrics Press, Elk Grove Village, IL
72. Daley-Yates P.T., and Richards D.H. Relationship between systemic corticosteroid exposure and growth velocity: development and validation of a pharmacokinetic/pharmacodynamic model. Clin Ther 26 (2004) 1905-1919
73. Foster B.J., Shults J., Zemel B.S., and Leonard M.B. Interactions between growth and body composition in children treated with high-dose chronic glucocorticoids. Am J Clin Nutr 80 (2004) 1334-1341
74. Stuart F.A., Segal T.Y., and Keady S. Adverse psychological effects of corticosteroids in children and adolescents. Arch Dis Child 90 (2005) 500-506
75. Bender B.G., Ikle D.N., DuHamel T., and Tinkelman D. Neuropsychological and behavioral changes in asthmatic children treated with beclomethasone dipropionate versus theophylline. Pediatrics 101 (1998) 355-360
76. Balaban B., Matthews D.J., Clayton G.H., and Carry T. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect. Am J Phys Med Rehabil 84 (2005) 843-850
77. Mortimer K.J., Tata L.J., Smith C.J., et al. Oral and inhaled corticosteroids and adrenal insufficiency: a case-control study. Thorax 61 (2006) 405-408
78. In: Brunton L.L., Lazo J.S., and Parker K.L. (Eds). Goodman and Gilman's the pharmacological basis of therapeutics. 11th edn. (2005), McGraw-Hill Medical, New York
79. Brown J.J., and Zacharin M.R. Proposals for prevention and management of steroid-induced osteoporosis in children and adolescents. J Paediatr Child Health 41 (2005) 553-557
80. Garrood P., Eagle M., Jardine P.E., Bushby K., and Straub V. Myoglobinuria in boys with Duchenne muscular dystrophy on corticosteroid therapy. Neuromuscul Disord 18 (2008) 71-73
81. Brooke M.H., Fenichel G.M., Griggs R.C., et al. Clinical investigation in Duchenne dystrophy: 2. Determination of the power of therapeutic trials based on the natural history. Muscle Nerve 6 (1983) 91-103
82. Bushby K., Griggs R., and MSG/ENMC FOR DMD trial study group. 145th ENMC International Workshop: planning for an international trial of steroid dosage regimes in DMD (FOR DMD), 22-24th October 2006, Naarden, The Netherlands. Neuromuscul Disord 17 (2007) 423-428
83. Biggar W.D., Gingras M., Fehlings D.L., Harris V.A., and Steele C.A. Deflazacort treatment of Duchenne muscular dystrophy. J Pediatr 138 (2001) 45-50
84. Escolar D.M., Buyse G., Henricson E., et al. CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy. Ann Neurol 58 (2005) 151-155
85. Cyrulnik S.E., Fee R.J., Batchelder A., Kiefel J., Goldstein E., and Hinton V.J. Cognitive and adaptive deficits in young children with Duchenne muscular dystrophy (DMD). J Int Neuropsychol Soc 14 (2008) 853-861
86. Green J.M., and Murton F.E. Diagnosis of Duchenne muscular dystrophy: parents' experiences and satisfaction. Child Care Health Dev 22 (1996) 113-128
87. Nereo N.E., Fee R.J., and Hinton V.J. Parental stress in mothers of boys with Duchenne muscular dystrophy. J Pediatr Psychol 28 (2003) 473-484
88. Anderson J.L., Head S.I., Rae C., and Morley J.W. Brain function in Duchenne muscular dystrophy. Brain 125 (2002) 4-13
89. Kazdin A.E., and Weisz J.R. Evidence-based psychotherapies for children and adolescents (2003), Guilford Press, New York
90. Hendriksen J.G., Poysky J.T., Schrans D.G., Schouten E.G., Aldenkamp A.P., and Vles J.S. Psychosocial adjustment in males with Duchenne muscular dystrophy: psychometric properties and clinical utility of a parent-report questionnaire. J Pediatr Psychol 34 (2009) 69-78
91. Hinton V.J., De Vivo D.C., Nereo N.E., Goldstein E., and Stern Y. Selective deficits in verbal working memory associated with a known genetic etiology: the neuropsychological profile of Duchenne muscular dystrophy. J Int Neuropsychol Soc 7 (2001) 45-54
92. Cyrulnik S.E., Fee R.J., De Vivo D.C., Goldstein E., and Hinton V.J. Delayed developmental language milestones in children with Duchenne's muscular dystrophy. J Pediatr 150 (2007) 474-478
93. Cotton S.M., Voudouris N.J., and Greenwood K.M. Association between intellectual functioning and age in children and young adults with Duchenne muscular dystrophy: further results from a meta-analysis. Dev Med Child Neurol 47 (2005) 257-265
94. Hendriksen J.G., and Vles J.S. Are males with Duchenne muscular dystrophy at risk for reading disabilities?. Pediatr Neurol 34 (2006) 296-300
95. Hendriksen J.G., and Vles J.S. Neuropsychiatric disorders in males with duchenne muscular dystrophy: frequency rate of attention-deficit hyperactivity disorder (ADHD), autism spectrum disorder, and obsessive-compulsive disorder. J Child Neurol 23 (2008) 477-481
96. Daoud M.A., Dooley J.M., and Gordon K.E. Depression in parents of children with Duchenne muscular dystrophy. Pediatr Neurol 31 (2004) 16-19